Nestlé subsidiary Aimmune Therapeutics has won European Commission approval of its peanut allergy treatment, Palforzia, for patients aged 4 to 17 years in the European Union (EU).

In late-stage trials, more than half of patients taking Palforzia safely tolerated the “equivalent of seven to eight peanut kernels” following up to nine months of treatment, Aimmune said.

Palforzia’s approval marks the first EU-approved peanut allergy treatment. The company is planning a May 2021 launch of the product in Germany and the UK.